Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.
Also called NCT03459079
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 128 participants
- Sponsor
- Registry
-
NCT03459079
-
- Other papers using this trial's data
- Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03459079. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-14 (actual); primary completion 2023-04-18 (actual). Results posted on 2024-09-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
- Condition
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Condition
- Type 2 Diabetes (T2DM)
- Intervention (Drug)
- Lanifibranor
- Intervention (Other)
- Placebo
- Lead sponsor
- University of Florida
- Collaborator
- Inventiva Pharma
Record details
- Record id
cardio:ct-nct03459079- Content hash
13eba13391c258f4ff1d9d3f5d02eb84e910673ec0011c734fab48b21504f1c4